Investor Presentation Q1 2018

Investor Presentation First three months of 2018 Slide 49 Sustained leadership position in the European modern and new-generation insulin market European insulin market by segment Device penetration CAGR volume¹: 4.3% CAGR value¹: 4.8% European modern insulin and new-generation insulin volume market shares Sanofi Novo Nordisk Eli Lilly - tMU 180 160 140 120 100 80 60 40 20 0 Feb 2013 - MI and NGI penetration Penetration 100% 60% 50% 80% Fast-acting 40% 60% 30% Premix 40% 20% Long-acting 20% 10% 0% 0% Feb 2018 Feb 2013 1 CAGR for 5-year period 2 MI: Modern insulin; NGI: New-generation insulin Source: IQVIA monthly MAT Feb, 2018 volume and value (DKK) figures changing diabetes® 44% 36% 19% Feb 2018 Source: IQVIA monthly MAT Feb, 2018 volume figures, numbers do not add up to 100% due to smaller insulin manufacturers novo nordisk

View entire presentation